pomalidomide has been researched along with Lung Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belal, A; Ma, X; O Aboelez, M; Xiang, G | 1 |
| Qi, Z; Wang, X; Zhao, Y | 1 |
| Bartlett, JB; Chen, RS; Hariri, RJ; Hughes, CC; Lu, L; Man, HW; Muller, GW; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L; Zhang, LH | 1 |
| Beck, R; Ellis, PM; Fandi, A; Jungnelius, U; Shepherd, FA; Zhang, J | 1 |
1 trial(s) available for pomalidomide and Lung Neoplasms
| Article | Year |
|---|---|
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thalidomide | 2013 |
3 other study(ies) available for pomalidomide and Lung Neoplasms
| Article | Year |
|---|---|
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Structure-Activity Relationship; Thalidomide | 2022 |
LY103, a pomalidomide derivative, alleviates taxol resistance in NSCLC via energy metabolism crosstalk and tumor microenvironment intervention.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Energy Metabolism; Humans; Lung Neoplasms; Molecular Docking Simulation; Paclitaxel; Tumor Microenvironment | 2023 |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; beta Catenin; Cadherins; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Lenalidomide; Lung Neoplasms; Melanoma, Experimental; Mice; Microcirculation; Neoplasm Metastasis; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy; Proto-Oncogene Proteins c-akt; Thalidomide; Umbilical Arteries | 2009 |